Adopted therapeutic plan | UKPDS RE at baseline | UKPDS RE after 12 months | UKPDS RE after 48 months | ||||||
---|---|---|---|---|---|---|---|---|---|
N | Mean (SD) | p Value | N | Mean (SD) | p Value | N | Mean (SD) | p Value | |
DPP4i (sitagliptin alone) | 8 | 1.28 (0.30) | 0.14 | 4 | 1.16 (0.17) | 0.003 | 5 | 1.13 (0.23) | 0.04 |
DPP4i+metformin | 70 | 1.21 (0.26) | 72 | 1.15 (0.27) | 74 | 1.20 (0.25) | |||
DPP4i+metformin+SU | 75 | 1.31 (0.25) | 75 | 1.28 (0.25) | 75 | 1.27 (0.26) | |||
DPP4i+metformin+SU+other | 1 | 1.28 (0.00) | 2 | 1.11 (0.28) | 1 | 1.25 (0.00) | |||
DPP4i+metformin+other | 4 | 1.46 (0.28) | 4 | 1.44 (0.24) | 4 | 1.40 (0.35) | |||
DPP4i+SU | 6 | 1.46 (0.13) | 7 | 1.48 (0.17) | 6 | 1.53 (0.19) | |||
DPP4i+SU+other | 1 | 1.23 (0.00) | 1 | 1.18 (0.00) | 1 | 1.23 (0.00) | |||
DPP4i+other | 5 | 1.34 (0.33) | 5 | 1.36 (0.31) | 4 | 1.52 (0.07) |
DPP4i, dipeptidyl peptidase-4 inhibitor (sitagliptin); other, other oral antihyperglycemic agents, or insulin therapy; SU, sulfonylureas; UKPDS RE, the UK Prospective Diabetes Study Risk Engine.